Symbiodx,Cure Forward Partner
News Sep 30, 2015
The partnership between Symbiodx and Cure Forward will provide patients with streamlined access to their genomic data and greater exposure to relevant clinical trials.
Symbiodx is an innovative, state-of-the-art anatomic and molecular pathology reference laboratory currently doing more than 300,000 biopsies annually. Symbiodx provides a unique solution for cancer genomics testing through a custom designed next generation sequencing (NGS) assay that incorporates the histopathology findings, and informs clinical decision-making for both solid and hematologic malignancies."Symbiodx pathologists and staff are involved with the diagnosis and care of more than 10,000 cancer patients per year. We are very proud of the quality and service we provide to our patients and their treating physicians. Partnering with Cure Forward will allow us to provide an additional service to our cancer patients in helping them connect with clinical trials.” Anna Berry, M.D Director of Molecular Pathology at Symbiodx.
Cure Forward launched in private beta earlier this year to streamline the connection between diagnosed cancer patients and clinical trial administrators. Through Cure Forward’s website, patients can retrieve molecular diagnostic test results ordered by their physicians from accredited laboratory test providers, and then use that data to access educational information, collaborate with other patients, or investigate treatment options including clinical trials. With its unique clinical trial matching technology, inverts conventional approaches to trial matching by bringing trial invitations directly to patients. The solution is intended to reduce recruitment times and increase trial participation, to support faster approval of targeted therapies for cancer patients.
“Bringing audiences together online is a type of innovation that has helped solve so many of life’s problems, from finding a ride to funding a startup. We decided to apply the same type of thinking to the challenge of complex disease,” said Martin Naley, Cure Forward CEO. “At Cure Forward, cancer patients use their medical data to unlock insights and opportunities that may change the course of their care. It begins with high-quality test data from leading clinical diagnostic laboratories. We’re pleased to announce another step toward our goal to help patients with the collaboration between Cure Forward and Symbiodx.”
In addition to the clinical trial exchange, Cure Forward also offers access to educational information, starting in cancer, to help consumers understand the molecular science of their disease, as well as an online community where patients with the same molecular and clinical factors can connect and collaborate.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.